Literature DB >> 15971035

[Significance of occult lymphatic tumor spread in pancreatic cancer].

C Milsmann1, L Füzesi, C Werner, H Becker, O Horstmann.   

Abstract

PURPOSE: The aim of this study was to determine the frequency and effect on prognosis of occult tumor cells in regional lymph nodes judged to be tumor-free in conventional histopathology of pancreatic cancer patients. PATIENTS AND METHODS: Among 115 patients who underwent pancreatic resection for pancreatic (n=84) or distal common bile duct malignancy (n=12) or carcinoma of the papilla (n=19), 48 (42%) were staged pN0. Archival paraffin blocks of 271 resected regional lymph nodes of 41 pN0 patients were reevaluated for occult tumor cells using monoclonal antibody Ber-EP4. Cases with or without isolated tumor cells were compared regarding the distribution of various clinicopathological factors.
RESULTS: Of 41 pN0 patients, 16 (39%) exhibited single Ber-Ep4 immunoreactive cells or small cell clusters in at least one lymph node. The occurrence of occult tumor cells was not dependent on other clinicopathological factors such as pT stage, grading, or curative resection. However, those cells were encountered more frequently in common bile duct carcinomas (100%) than in pancreatic (36%) or papilla (20%) carcinomas (P=0.009). Occult tumor cells impaired prognosis significantly in uni- and multivariate analyses (estimated 5-year survival 53% for pN0((i-)) vs 10% for pN0((i+)) and 9% for pN1/N2; P=0.0047).
CONCLUSION: Occult tumor cells are frequent in apparently tumor-free lymph nodes of pancreatic cancer patients and often overlooked in conventional histopathology. They are encountered even in limited stages of disease and they impair prognosis, which is comparable to that of patients with true lymphatic metastases. Occult tumor cells in lymph nodes of pancreatic cancer patients could be used to stratify adjuvant therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15971035     DOI: 10.1007/s00104-005-1041-y

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  29 in total

1.  Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance.

Authors:  K Dobashi; K Sugio; T Osaki; T Oka; K Yasumoto
Journal:  J Thorac Cardiovasc Surg       Date:  1997-09       Impact factor: 5.209

2.  Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma.

Authors:  T Fukagawa; M Sasako; G B Mann; T Sano; H Katai; K Maruyama; Y Nakanishi; T Shimoda
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

3.  Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer.

Authors:  Keiichiro Kanemitsu; Takehisa Hiraoka; Tatsuya Tsuji; Katsuhiko Inoue; Hiroshi Takamori
Journal:  Pancreas       Date:  2003-05       Impact factor: 3.327

4.  Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance.

Authors:  S B Hosch; W T Knoefel; S Metz; N Stoecklein; A Niendorf; C E Broelsch; J R Izbicki
Journal:  Pancreas       Date:  1997-08       Impact factor: 3.327

5.  Keratin-positive reticulum cells in fine needle aspirates and touch imprints of hyperplastic lymph nodes. A possible pitfall in the immunocytochemical diagnosis of metastatic carcinoma.

Authors:  W Domagala; E Bedner; M Chosia; K Weber; M Osborn
Journal:  Acta Cytol       Date:  1992 Mar-Apr       Impact factor: 2.319

6.  Significance of isolated tumor cells in lymph nodes among gastric cancer patients.

Authors:  Olaf Horstmann; Laszlo Füzesi; Peter M Markus; Carola Werner; Heinz Becker
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-17       Impact factor: 4.553

Review 7.  Pathology and biology of pancreatic ductal adenocarcinoma.

Authors:  P Hermanek
Journal:  Langenbecks Arch Surg       Date:  1998-04       Impact factor: 3.445

8.  Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma.

Authors:  E Tamagawa; M Ueda; S Takahashi; K Sugano; S Uematsu; M Mukai; Y Ogata; M Kitajima
Journal:  Clin Cancer Res       Date:  1997-11       Impact factor: 12.531

9.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.

Authors:  K Pantel; G Schlimok; M Angstwurm; D Weckermann; W Schmaus; H Gath; B Passlick; J R Izbicki; G Riethmüller
Journal:  J Hematother       Date:  1994

10.  Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes.

Authors:  R Jung; K Petersen; W Krüger; M Wolf; C Wagener; A Zander; M Neumaier
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

View more
  6 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Morphological and immunohistochemical characterization of isolated tumor cells by p53 status in gastrointestinal tumors.

Authors:  C Milsmann; L Füzesi; E Heinmöller; P Krause; C Werner; H Becker; O Horstmann
Journal:  Langenbecks Arch Surg       Date:  2007-09-18       Impact factor: 3.445

3.  Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy.

Authors:  Emre-F Yekebas; Dean Bogoevski; Michael Bubenheim; Björn-Christian Link; Jussuf-T Kaifi; Robin Wachowiak; Oliver Mann; Asad Kutup; Guellue Cataldegirmen; Lars Wolfram; Andreas Erbersdobler; Christoph Klein; Klaus Pantel; Jakob-R Izbicki
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 4.  Pancreatic cancer: a generalized disease--prognostic impact of cancer cell dissemination.

Authors:  D Bogoevski; T Strate; E F Yekebas; J R Izbicki
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

5.  Clinical and pathologic prognostic factors for curative resection for pancreatic cancer.

Authors:  M V Perini; A L Montagnini; J Jukemura; S Penteado; E E Abdo; R Patzina; I Cecconello; J E M Cunha
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

6.  Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer.

Authors:  Mayumi Hoshikawa; Sho Ogata; Makoto Nishikawa; Akifumi Kimura; Takahiro Einama; Takuji Noro; Suefumi Aosasa; Kazuo Hase; Hironori Tsujimoto; Hideki Ueno; Junji Yamamoto
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.